Post-Marketing Plans: An Often Overlooked Component of FDA Advisory Committee Meeting Discussions

Posted 22 December 2015 By Christen M. Anderson, MD, PhD

placeholder+image The article analyzes the proportion of FDA Advisory Committees specifically asked to discuss or vote on issues related to post-approval safety activities.

Share this article:

Categories: Postmarket surveillance, Features, US, FDA, Communication

Tags: Post-marketing Plans, Advisory Committee Meetings

Regulatory Exchange: Latest Updates From the Community